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ssessing Low Levels of High-Density Lipoprotein
holesterol as a Risk Factor in Coronary Heart Disease
Working Group Report and Update
ntonio M. Gotto, JR, MD, DPHIL,* Eliot A. Brinton, MD†
ew York, New York; and Phoenix, Arizona
Clinical data show that a 1% increase in serum concentrations of high-density lipoprotein
cholesterol (HDL-C) can decrease cardiovascular risk by 2% to 3%. Therefore, mechanisms
affecting the level and functionality of high-density lipoprotein (HDL) and its constituents
are being investigated as targets for the rational development of drugs to prevent or treat
cardiovascular disease. High-density lipoprotein-related research may also increase our
understanding of the link between atherosclerosis and metabolic disorders. This report and
update of the HDL Working Group discusses HDL metabolism and reverse cholesterol
transport, impaired HDL as a marker and a cause of proatherogenic states, and experimental
and current approaches to HDL-related therapy. (J Am Coll Cardiol 2004;43:717–24)
© 2004 by the American College of Cardiology Foundationm
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cn January 12 to 13, 2001, a distinguished international
roup of 25 investigators with expertise in epidemiology,
ndocrinology, molecular biology, public health, lipid me-
abolism, cardiovascular medicine, and preventive cardiol-
gy (Appendix) met in Scottsdale, Arizona, to discuss the
atest research on low levels of high-density lipoprotein
holesterol (HDL-C) as a risk factor for coronary heart
isease (CHD). It was the second meeting of a working
roup formed one year earlier to focus the attention of the
edical community on this issue. This article summarizes
he 2001 meeting and provides further information from
ecently published research.
The Working Group reached agreement on several points
Table 1), most importantly, that: 1) raising HDL-C levels is
seful in atheroprevention, in addition to reducing low-density
ipoprotein cholesterol (LDL-C) levels, and 2) further basic
nd clinical research is essential in order to improve our ability
o raise high-density lipoprotein (HDL) levels.
DL METABOLISM
ransport rate and fractional catabolic rate. Apolipoprotein
apo) A-I and apo A-II are the two major protein components
f HDL. In the general population, an inverse relation be-
ween CHD and plasma levels of apo A-I has been demon-
trated. However, an association between CHD risk and apo
-II levels has not been clearly shown, and the role of apo A-II
n atherogenesis is not well defined (1). Therefore, the follow-
ng discussion will focus primarily on HDL and apo A-I.
Turnover studies indicate that HDL-C levels are deter-
From the *Weill Medical College of Cornell University, New York, New York; and
he †University of Utah School of Medicine, Salt Lake City, Utah. The Working
roup meeting was supported by an unrestricted educational grant from Merck and
o. Inc. This article is based on speaker presentations, discussions by all of the
articipants, and research published after the meeting occurred.
Manuscript received July 17, 2002; revised manuscript received July 28, 2003,lccepted September 19, 2003.ined by the fractional catabolic rate (FCR) of apo A-I and
po A-II (2–4). The transport rate (TR) of apo A-I and apo
-II generally plays a less important role in regulating
DL-C levels (2,5), except in certain circumstances (such
s intake of ethanol and saturated fat) (6,7).
The apo A-I FCR is largely a function of HDL lipid
ontent (and, therefore, size). Consequently, plasma factors
hat participate in the remodeling of HDL particles are
rucial. These include lipid transfer proteins (e.g., cho-
esteryl ester transfer protein [CETP]) and the enzymes
ecithin:cholesterol acyltransferase (LCAT), lipoprotein
ipase (LPL), and hepatic lipase (HL) (Fig. 1) (8). Lecithin:
holesterol acyltransferase and lipoprotein lipase are major
actors in the production of HDL, whereas CETP and HL
re involved in its catabolism.
The efflux of free cholesterol from peripheral cells is
nother major factor regulating HDL lipid content, size,
CR, and plasma level. This is the first step in reverse
holesterol transport (RCT), the process whereby HDL
ransports cholesterol to the liver for biliary excretion. Free
holesterol is taken up by small lipid-poor apo A-I particles
“nascent” HDL), which are secreted in the liver and are
ighly efficient acceptors of cell membrane lipids.
Cellular cholesterol efflux is mediated by the ABC-A1
egulatory protein (9). Mutations in the ABC-A1 gene
revent cholesterol efflux, leading to a rapid clearance of
mall lipid-poor apo A-I from plasma and sterol deposition
n macrophages (10,11). Heterozygotes can have hypoal-
halipoproteinemia; homozygotes or compound heterozy-
otes have Tangier disease (TD), with severe decreases in
DL size, lipidation, and levels, and hypercatabolism of
po A-I (10–12). Interestingly, very small dense lipid-poor
DL particles may play a dual role in regulating HDL
oncentration (13). Nascent particles are crucial to extracel-
ular HDL maturation; however, “senescent” HDL particles
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Assessing Low Levels of HDL-C as a CHD Risk Factor March 3, 2004:717–24enerated by the actions of lipid transfer proteins or endo-
helial lipases are highly susceptible to renal glomerular
ltration (Fig. 1), which increases the FCR of apo A-1 and
ay lead to low levels of HDL-C and apo A-1 (13).
Hypertriglyceridemia is strongly associated with low
DL-C levels (14), and the FCR of apo A-I is elevated in
atients with this combined lipid abnormality. Even when
riglycerides are normal, however, persons with low
DL-C tend to have small HDL-C particles and elevated
CR (3), perhaps resulting from lipase overactivity inde-
endent of a primary increase in triglycerides (14).
Niacin (nicotinic acid), probably the most effective HDL-
–raising agent, decreases the FCR of apo A-I (15). In
ontrast, fibrates, statins, and oral estrogen raise HDL-C levels
y increasing the TR (16–18). Ethanol also raises HDL levels
y increasing the TR of apo AI (6); however, the risks
ssociated with promoting alcohol consumption are generally
onsidered to make this an inadvisable HDL-raising strategy.
ome believe that grapeseed oil has an HDL-raising effect, but
here is a lack of scientific evidence to support this.
Abbreviations and Acronyms
ABC-A1  adenosine triphosphate binding cassette-A1
apo  apolipoprotein
CETP  cholesteryl ester transfer protein
CHD  coronary heart disease
FCR  fractional catabolic rate
HDL-C  high-density lipoprotein cholesterol
HL  hepatic lipase
LCAT  lecithin:cholesterol acyltransferase
LDL-C  low-density lipoprotein cholesterol
PPAR  peroxisome proliferator activated receptor
RCT  reverse cholesterol transport
SR-B1  scavenger receptor B1
VLDL  very low-density lipoprotein
able 1. HDL as a Therapeutic Target: HDL Working Group
onsensus
HDL and its constituents are rational targets of cardiovascular therapy.
HDL appears to have several atheroprotective properties, although
RCT may be the primary mechanism.
Impaired HDL is a cause and a marker of proatherogenic states.
Promising experimental approaches that may maximize the athero-
protective activity of HDL-C include:
stimulating apo A-I production, which may promote RCT
targeting other mechanisms related to RCT
targeting the metabolic syndrome
targeting other antiatherogenic properties of HDL
slowing HDL or apo A-I turnover
Methods must be developed to measure the rates of cholesterol efflux
and RCT.
HDL-C–related interventions, both lifestyle and pharmacologic,
should be used in conjunction with strategies aimed at modifying
other lipid abnormalities (e.g., LDL-C, triglycerides).
Optimal HDL-C–raising benefit may be derived from combination
therapy in some patients.
Continued basic research is essential in order to identify molecular
targets for future drug development.
po  apolipoprotein; HDL-C high-density lipoprotein cholesterol; LDL-C 
low-density lipoprotein cholesterol; RCT  reverse cholesterol transport.everse cholesterol transport. The reverse cholesterol
ransport begins with the uptake of cholesterol from peripheral
ells, perhaps especially arterial wall macrophages, by nascent
DL. These particles are remodeled into mature HDL2
hrough the activity of LCAT, which catalyzes the esterifica-
ion of cholesterol, and LPL, which hydrolyzes triglycerides in
irculating lipoproteins, generating surface components that
ontribute to HDL enlargement (3,19). Cholesteryl ester
ransfer protein then mediates the delivery of much of the
sterified HDL cholesterol to apo-B–containing lipoproteins
n exchange for triglycerides (Fig. 1) (20).
The HDL particles generated by CETP-mediated activ-
ty are enriched in triglycerides relative to their cholesteryl
ster content (21). Following HL-mediated hydrolysis of
he triglyceride component, the cholesteryl esters undergo
learance by the SR-B1 receptor (22). This process is
ermed “direct” RCT, because the cholesterol has been
ssociated with the HDL since its initial uptake from
eripheral cells (22). The SR-B1 clearance results in lipid-
epleted HDL particles that may be susceptible to enhanced
lomerular filtration, as well as catabolism by other tissues
13,23). This accounts for a substantial portion of apo A-I
atabolism. Paradoxically, oral estrogen appears to suppress
L activity without a corresponding decrease in the FCR of
po A-I or apo A-II (18).
Niacin decreases the FCR of apo A-I, reportedly by
electively reducing hepatic uptake of HDL apo A-I with-
ut impairing hepatic uptake of HDL cholesteryl esters.
he resulting increase in levels of apo A-I containing HDL
articles augments RCT by promoting apo A-I–mediated
ellular cholesterol efflux (15).
A major advance in our understanding of cholesterol
etabolism has been the recognition of a second major
athway involved in the return of cholesterol to the liver.
holesteryl ester transfer protein transfers much of the
DL cholesteryl esters to very low-density lipoprotein
VLDL) or LDL particles. The esterified cholesterol is
ransported by these particles (or their remnant lipopro-
eins) to the liver, where they are taken up by the LDL
eceptor in a process known as “indirect” RCT (22).
Our understanding of RCT has also been enhanced by the
tudy of the ABC-A1 transporter and TD. Research in
ransgenic mice found that overexpression of human ABC-A1
ed to marked increases in apo A-I and HDL-C levels and to
ignificantly lower aortic atherosclerosis (24). However, an-
ther transgenic mouse study involving ABC-A1 overexpres-
ion found increased cholesterol efflux without a corresponding
ise in HDL level, possibly because of a compensatory down-
tream increase in HDL catabolism (25). This illustrates the
omplexity of RCT.
A related lipid transporter, ABC-G1, is up-regulated by
holesterol in macrophages and may provide a compensatory
oute of residual cholesterol and phospholipid efflux in TD
atients (26). Paradoxically, however, a transgenic mouse study
eported that overexpression of human ABC-G1 in the liver
ed to decreased plasma HDL-C and apo A-I levels (27). The
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March 3, 2004:717–24 Assessing Low Levels of HDL-C as a CHD Risk Factorechanism for this effect is unclear, because there was no
p-regulation of the SR-B1 receptor, believed to be the main
cceptor of cholesteryl ester in the liver (28), or of cubilin,
hich mediates endocytosis of apo A-I in the kidney.
lasma factors. Forty percent to 60% of the interindividual
ariation in human serum HDL-C concentrations is con-
rolled at the genetic level, and the strong positive correlation
etween plasma levels of apo A-I and HDL-C suggests that
utant apo A-I genes may be linked to variability in HDL-C
evels (29). More than 40 naturally occurring human apo A-I
oding-sequence mutations have been identified, of which
oughly half are linked to below-average plasma concentrations
f HDL apo A-I (30). Among these, deletion of repeats 6 or
(residues 143 to 186) dramatically decreases the ability of
CAT, for which apo A-I is a co-factor, to catalyze the
sterification of cholesterol. This blocks the maturation of
ascent HDL, resulting in hypercatabolism of lipid-poor apo
-I and lower HDL levels (30).
Genetic polymorphisms in plasma factors active in HDL
etabolism may help predict response to lipid-modifying
herapy. In one study, a C3T substitution at position514 in
he promoter region of the HL gene was associated with
ecreased benefit in patients treated with lovastatin or niacin.
ompared with the TT genotype, patients with the CC
olymorphism had a greater decrease in HL activity, greater
ncrease in LDL buoyancy, normalization of HDL2-C levels,
nd improvements in LDL-C and apo B levels and in coronary
igure 1. This figure illustrates reverse cholesterol transport, which deliv
denosine triphosphate binding cassette (ABC)-A1 transporter mediates
polipoprotein (apo) A-I–rich nascent high-density lipoprotein (HDL)
ormation of mature spherical HDL2 particles. Following cholesteryl est
riglycerides, the latter are hydrolyzed by hepatic lipase (HL). The CE still a
eceptor B1 (SR-B1) in the liver (“direct” reverse cholesterol transport [RC
usceptible to glomerular filtration and endocytosis by the cubilin/megali
po-B–containing particles (very low-density lipoprotein [VLDL], interme
o the liver for uptake by the LDL receptor (“indirect” RCT). Courtesy o
ith permission. LDL-R  low-density lipoprotein receptor; LPL  lipotenosis (31). Clinical end points were not evaluated. sIn the Regression Growth Evaluation Statin Study (RE-
RESS), the TaqIB polymorphism of the CETP gene (des-
gnated as B1) was associated both with progression of coro-
ary atherosclerosis and angiographic response to statin
herapy. Placebo-treated carriers of the B1/B1 genotype had
he greatest disease progression, as measured by change in
umen diameter, compared with B2/B2 (denoting absence of
he variant) and B1/B2 carriers. This relation was independent
f HDL-C levels, although B1/B1 subjects had higher CETP
nd lower HDL-C concentrations at baseline compared with
2/B2 subjects. In addition, pravastatin slowed atherosclerosis
rogression significantly in B1/B1 and B1/B2 carriers versus
lacebo, whereas B2/B2 carriers experienced no treatment
enefit (32). This study did not examine clinical end points.
owever, plaque size may not be an appropriate surrogate for
linical benefit, because acute coronary syndromes appear to
esult largely from vulnerable plaques that are only mildly or
oderately obstructive (33).
OW HDL-C: CAUSE OR MARKER
F PROATHEROGENIC STATES?
ow HDL-C levels may directly promote atherogenesis,
articularly when there is some elevation in LDL-C; often
ccur in the presence of increased concentrations of
therogenic lipoproteins (e.g., triglyceride-rich VLDL rem-
ants, small LDL particles); and are often part of the metabolic
olesterol from peripheral cells to the liver for excretion in the bile. The
efflux of free cholesterol from peripheral cells, notably macrophages, to
rification by lecithin:cholesterol acyltransferase (LCAT) results in the
nsfer protein (CETP)-mediated exchange of cholesteryl esters (CE) for
ted with HDL2 are then selectively removed from plasma by the scavenger
resulting in small, lipid-poor apo A-I particles (senescent HDL) that are
eptors in the renal proximal tubule. A portion of the CE transferred to
density lipoprotein [IDL], low-density lipoprotein [LDL]) are transported
g T. Basson, MD, PhD, and Carl J. Vaughan, MD, MRCPI. Reprinted
in lipase; mLDL  modified low-density lipoprotein.ers ch
the
. Este
er tra
ssocia
T]),
n rec
diate-
f Craiyndrome, a constellation of lipid, nonlipid (e.g., hypertension,
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Assessing Low Levels of HDL-C as a CHD Risk Factor March 3, 2004:717–24mpaired fasting glucose), and emerging (e.g., prothrombotic/
roinflammatory states) risk factors. Under certain conditions,
uch as the presence of infection, the roles of HDL-C as
arker and causative agent may be intertwined.
During the acute-phase response, HDL levels decrease and
DL metabolism is altered (34,35). For example, in a rabbit
odel, levels of serum amyloid A (SAA), whose synthesis in
he liver is largely regulated by acute-phase reactants (cyto-
ines), were shown to increase 60-fold during an inflammatory
tress, while levels of apo A-I declined. There was also a
arked decrease in the activity of enzymes that render HDL
rotective against LDL oxidation, with a parallel loss of HDL
ntioxidant activity (36). An accompanying study found that
uman acute-phase HDL had elevated SAA content and 58%
ower apo A-I content, and promoted (rather than prevented)
DL oxidation in human aortic endothelial cell and smooth
uscle cell coculture (36). Thus, infection or inflammation
ppears to cause proatherogenic changes in both concentration
nd function of HDL.
DL-C AS A THERAPEUTIC
ARGET IN MANAGING CHD
ot only are low HDL-C concentrations often found in
atients with CHD (37), but genetic syndromes of high
DL-C have been linked to longevity and a rare occurrence
f premature cardiac events (38).
xperimental approaches to HDL-related therapy. Ex-
erimental evidence suggests that augmenting HDL and/or its
polipoproteins can have important vasoprotective effects (39).
owever, precise methods for measuring the rates of choles-
erol efflux and RCT must be developed to evaluate any
trategy aimed at stimulating RCT. The following experimen-
al approaches seem to offer promise (Table 1).
TIMULATING APO A-I PRODUCTION. Heightened produc-
ion of apo A-I may increase the quantity of acceptors
vailable for cholesterol removal from cells. It may also
timulate LCAT, which could promote cellular cholesterol
fflux and enhance the efficiency of RCT (26). In transgenic
abbits, overexpression of human apo A-I was shown to
ncrease HDL-C levels two-fold and inhibit the develop-
ent of atherosclerosis (40).
In a recent phase II study (N  57), weekly intravenous
nfusion of recombinant apo A-I Milano (ETC-216) begun
ithin two weeks of an acute coronary event and adminis-
ered for five weeks led to a significant reduction in
theroma (plaque) volume, as measured by intravascular
ltrasound, compared with baseline. It should be noted,
owever, that the change in the treated group did not differ
ignificantly from that in placebo. For this and other
easons, this novel treatment requires further study in larger
rials with clinical end points (42).
Although macrophages do not secrete apo A-I, the ability of
xtracellular apo A-I to promote cellular cholesterol efflux
uggests that the induction of apo A-I expression in macro-
/hages may achieve a similar effect. In one study of apo A-I bransgenic mice, macrophage-specific expression of human apo
-I reduced diet-induced arterial lesions, substituting for the
ntiatherogenic effects of macrophage-derived apo E. This
ndicates that gene therapy using macrophages to target the
rtery wall may have promise (43).
Apo A-I and apo A-II gene induction is mediated by
eroxisome proliferator-activated receptors (PPARs). Con-
tituting a nuclear receptor subfamily, PPARs are ligand-
ctivated transcription factors that regulate a wide range of
enes either directly, by binding to peroxisome proliferator
esponse elements within the gene, or indirectly, by inter-
cting with other transcription-factor pathways (44,45).
PAR-alpha is highly expressed in liver, muscle, kidney,
nd heart tissue and is primarily involved in lipid metabo-
ism (45,46). PPAR-gamma, predominantly expressed in
he intestine and adipose tissue, primarily regulates insulin
nd glucose metabolism, but also affects lipid metabolism
47,48). Both are present in monocyte/macrophages, endo-
helial cells, and smooth muscle cells in the vascular wall
45), and both may induce expression of the ABC-A1 gene,
hich is found in human monocyte/macrophages and mac-
ophage foam cells (48). Fatty acids and their derivatives are
atural PPAR ligands, whereas fibrates, statins, and thiazo-
idinediones (glitazones) are synthetic PPAR activators
16,49,50).
In patients with hypertriglyceridemia, combined hyper-
ipidemia, or hypercholesterolemia, fibrates raise HDL-C
evels by roughly 10% to 15%, at least in part through
nduction of the apo A-I and apo A-II genes via activation
f PPAR-alpha (46). Recently, statins were also shown to
ctivate PPAR-alpha, and a statin response element in the
po A-I gene was identified in the same region as the
eroxisome proliferator response elements that confers re-
ponsiveness to fibrates (49).
ARGETING OTHER RCT-RELATED MECHANISMS. The
cavenger receptor is another potential therapeutic target.
verexpression of hepatic SR-B1 in animals can reduce
therosclerosis while paradoxically lowering plasma HDL-C
oncentrations, perhaps by stimulating the rate of RCT (51).
fforts to increase HDL levels by inhibiting CETP pose a
uandary, because CETP appears to have both proatherogenic
nd antiatherogenic properties. It may be proatherogenic by
ediating the transfer of esterified cholesterol from HDL to
po-B–containing lipoproteins, thereby decreasing HDL-C
nd raising VLDL-C and LDL-C levels. However, the
sterified cholesterol transferred to apo-B-containing particles
s transported to the liver, where it is removed from plasma by
he LDL receptor. This suggests an antiatherogenic effect.
xperts are investigating whether CETP activity can be
imited in a way that will not be negated by a decrease in RCT.
n rabbit models, a vaccine that elicits CETP antibodies and a
ETP inhibitor were shown to raise HDL-C levels and
ecrease the size of atherosclerotic lesions compared with
ontrols (52,53). Trials of CETP inhibitors have recently
egun in humans.
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March 3, 2004:717–24 Assessing Low Levels of HDL-C as a CHD Risk FactorIn Asian and Caucasian populations, more than 10
llelic variants of mutations and polymorphisms in the
oding region of the CETP gene have been identified.
hese include the TaqIB (discussed earlier), I405V, and
442G polymorphisms (54). The D442G polymorphism is
he most common and has been linked to a CETP defi-
iency. Found only in Asian populations, it is associated
ith an increased risk for CHD in subjects with relatively
ow HDL-C levels (45 mg/dl), but not in those with
DL-C levels 60 mg/dl. Other research has demon-
trated that low CETP activity associated with the I405V
olymorphism, which occurs in Asian and Caucasian pop-
lations, confers increased vascular risk in the presence of
ypertriglyceridemia. Such data suggest that a patient’s
etabolic status may influence the effect of CETP on
therosclerosis (54). If substantiated, this could have impli-
ations for the development of CETP-based therapies.
ARGETING THE METABOLIC SYNDROME. The metabolic
yndrome, which increases the risk for CHD at any LDL-C
evel, is associated with low HDL-C, elevated TG, insulin
esistance, abdominal obesity, and physical inactivity (55); it
ay also lead to type 2 diabetes. Recently recognized as an
mportant endocrine organ, adipose tissue secretes a number
f factors (adipokines) that regulate, directly or indirectly,
rocesses (such as insulin resistance) that promote athero-
enesis (56,57). In addition, a strong correlation has been
hown between intra-abdominal fat and the FCR of Lp-AI,
he apo A-I–containing subfraction of HDL. One possible
xplanation for this effect is that intra-abdominal adipocytes
elease excess free (unesterified) fatty acids. Hepatic expo-
ure to this excess may lead directly or indirectly to hyper-
atabolism of apo A-I mediated by the plasma factors
escribed earlier (58).
Thiazolidinediones are insulin sensitizers indicated for
ype 2 diabetes. They also appear to be useful in the
etabolic syndrome (59). As synthetic ligands of PPAR-
amma, thiazolidinediones reduce free fatty acid levels (60),
robably by enhancing adipogenesis and/or lowering rates
f lipolysis in adipocytes (50). This diminishes the amount
f substrate available for triglyceride production in the liver,
eading to a decrease in triglyceride levels and thus possibly
ontributing to elevated HDL-C concentrations. PPAR-
amma activation may also induce expression of the
BC-A1 transporter gene via enhanced expression of the
iver-x-receptor co-factor, which may help explain the
ncrease in HDL levels with thiazolidinedione use (45,61).
ARGETING OTHER ANTIATHEROGENIC PROPERTIES OF
DL. The benefit of some therapies may arise from changes
n the functionality or concentrations of HDL constituents
r subclasses, rather than from changes in total plasma
DL-C levels (62). For example, the HDL-associated
rotein apo E has antioxidant properties (63,64) that may
nhibit oxidative modification of LDL. Other forms of
theroprotection that may relate to HDL subspecies or
omponents include inhibition of endothelial adhesion mol- wcule expression, anticoagulant activity, prostacyclin stabili-
ation, and activation of endothelial nitric oxide synthase,
hich may promote vasodilation (61).
LOWING HDL OR APO A-I TURNOVER. Renal degradation
f HDL/lipid-poor apo A-I takes place in the proximal
enal tubule via cubilin/megalin endocytosis of particles that
ave been filtered across the glomerulus. Because filtered
po A-I particles cannot return to the plasma, cubilin/
egalin does not play a role in determining their rate of
atabolism. Instead, a principal determining factor is likely
he glomerular filtration rate of the HDL/apo-A-I particles,
s regulated by their physicochemical properties (size,
hape, charge) (23). Smaller HDL particles and/or lipid-
oor/lipid-free apo A-I dissociated from HDL are available
or rapid clearance via glomerular filtration (13,23). Conse-
uently, inhibition of HDL remodeling to smaller particles
ay reduce HDL catabolism and raise HDL levels.
linical approaches to HDL-C–related therapy. BENEFITS
F RAISING HDL-C LEVELS: CLINICAL TRIAL EVI DENCE. Epi-
emiologic data indicate that a 1 mg/dl increase in HDL-C
evels is associated with a 2% to 3% reduction in CHD risk,
ndependent of LDL-C levels (65). Thus, even modest incre-
ents in HDL-C concentrations appear to be clinically
mportant.
In a study comparing extended release niacin versus
emfibrozil, significant increases of 25% versus 13% in
DL-C levels and 10% versus 2.5% in apo A-I levels were
eported (66). Associated in vitro analyses suggest that
iacin may selectively inhibit the hepatic uptake of Lp-AI,
s discussed earlier, thereby raising concentrations of the
DL Lp-AI subfraction. This may facilitate more efficient
CT by promoting cellular cholesterol efflux (15), which
ould be consistent with reductions in cardiovascular out-
omes seen in other niacin trials (67–69).
Conducted between 1966 and 1975, the Coronary Drug
roject found that niacin significantly reduced the incidence
f nonfatal myocardial infarction compared with placebo.
lthough a trend toward decreased mortality was not
ignificant, a follow-up conducted in 1981 reported a
ignificant 11% reduction in mortality in the niacin-treated
atients. One possible explanation for this late benefit is
hat the early decrease in nonfatal myocardial infarction may
ave translated into a long-term effect on mortality (67).
In the Air Force/Texas Coronary Atherosclerosis Preven-
ion Study (AFCAPS/TexCAPS), lovastatin in patients with
elow-average HDL-C and average LDL-C levels increased
DL-C concentrations by 6%. LDL-C and triglyceride levels
ecreased by 25% and 15%, respectively (70). Participants
xperienced a 37% reduction in risk for a major coronary event,
ith the greatest reductions (45% and 44%) occurring in
atients in the lower two tertiles of baseline HDL-C (71). Just
7% of the patients in this study would have been eligible for
ipid-lowering therapy based on the National Cholesterol
ducation Program (NCEP) guidelines in effect at the time,
hich underscores the importance of raising HDL-C levels in
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Assessing Low Levels of HDL-C as a CHD Risk Factor March 3, 2004:717–24atients whose LDL-C levels may not be considered high. The
FCAPS/TexCAPS and the Lipoprotein and Coronary Ath-
rosclerosis Study, an atherosclerosis regression trial, indicate
hat patients with low HDL-C levels may be especially
esponsive to treatment with lovastatin or fluvastatin, respec-
ively (70,72).
Statins may differ in their effects on HDL-C. In one
2-week study comparing rosuvastatin 5 mg and 10 mg with
torvastatin 10 mg, rosuvastatin produced significantly
reater increases in HDL (13% and 12%, respectively)
nd apo A-I than did atorvastatin 10 mg (8%) (73).
xperimental studies are beginning to explore the nature
nd mechanisms of these differences among statins.
In selected patients, combination therapy may be consid-
red. The HDL Atherosclerosis Treatment Study (HATS)
ound that niacin plus simvastatin lowered the risk for major
oronary events by 60% to 90% in patients with coronary artery
isease, moderately elevated LDL-C levels, and HDL-C levels
35 mg/dl (men) or 40 mg/dl (women) (69). This was
ccompanied by regression of stenosis, rather than slowed
rogression. Overall, HDL levels increased by 26% and Lp-AI
evels rose by 81%. In a double-blind dose-ranging study, a
ormulation containing niacin extended release 2,000 mg and
ovastatin 40 mg improved overall lipoprotein profiles, includ-
ng a 30% increase in HDL-C levels, compared with niacin
xtended release 1,000 mg/lovastatin 40 mg or lovastatin 40
g. These results suggest a possible additive effect on CHD
isk reduction (74).
In the Veterans Affairs High-Density Lipoprotein Inter-
ention Trial (VA-HIT) (75), gemfibrozil did not decrease
DL-C levels in men with CHD and low HDL-C con-
entrations. However, HDL-C levels rose by 6% (along
ith a reduction in triglyceride levels) compared with
aseline. Although this was accompanied by a 22% decrease
n the incidence of coronary events, regression analyses
ndicate that lipid concentrations accounted for only part of
he benefit achieved with drug therapy (76).
Some studies indicate that alpha-blockers for the treat-
ent of hypertension can raise HDL-C levels and improve
ther lipid subfractions. In one 22-week randomized trial
nvolving 45 men with central obesity, doxazosin signifi-
antly increased HDL-C levels and lowered triglycerides
ompared with atenolol, a beta-blocker (77). A meta-
nalysis of 22 randomized controlled trials also found that
lpha-blockers favorably modified HDL-C levels when
ompared with placebo or other antihypertensive regimens
78). Doxazosin appears to increase insulin sensitivity and
mprove insulin resistance as well (78,79). In the Antihy-
ertensive and Lipid-Lowering to Prevent Heart Attack
rial (ALLHAT), the risk for fatal CHD/nonfatal myo-
ardial infarction was equal with doxazosin and chlorthali-
one. However, the doxazosin-treated patients had signifi-
antly higher rates of combined CHD and cardiovascular
vents, which led investigators to discontinue this arm of the
rial. At baseline, mean HDL-C levels were 47 mg/dl in Toth treatment groups, and 12% of the participants had
DL-C levels 35 mg/dl (80).
CEP GUIDELINES. As in previous NCEP guidelines for
etecting, evaluating, and treating high blood cholesterol,
he 2001 recommendations identify LDL-C reduction as
he primary goal of risk-reduction therapy (55).
In intermediate-risk patients, an HDL-C level 40
g/dl is one of several major risk factors that help deter-
ine the LDL-C goal and predict the 10-year risk for
HD. The guidelines also discuss HDL-C in relation to
he metabolic syndrome, which is clinically characterized by
ny three of the following: abdominal obesity, elevated TG
evels, low HDL-C levels, elevated blood pressure, and
mpaired fasting glucose. After LDL-C levels have been
owered, the metabolic syndrome is a potential secondary
oal of therapy; it is treated primarily by weight reduction
nd intensified physical activity. Although low HDL-C
evels are considered to be a strong independent predictor of
HD, the guidelines assert that there is insufficient clinical
rial evidence to support a therapeutic goal and, moreover,
hat most currently available lipid-modifying medications
ave little ability to produce a robust increase in HDL-C
evels. Nevertheless, after LDL-C goals have been achieved,
he guidelines suggest that niacin or fibrates be considered
s treatment for isolated low HDL-C (that is, accompanied
y TG levels 200 mg/dl), primarily in patients with
stablished CHD or CHD risk equivalents.
Lifestyle measures, including weight loss and physical
ctivity, are important in raising HDL-C levels. In the case
f aerobic exercise, duration appears to be more important
han intensity. Omega-3 fatty acids (fish oil), particularly
icosapentaenoic acid and docosahexaenoic acid, may have a
odest effect on HDL-C levels (81).
ONCLUSIONS
growing body of evidence indicates that HDL has an
thero-protective effect. Although the 2001 NCEP guide-
ines state that there is insufficient evidence to support a goal
or HDL-C–raising therapy (55), clinical trial results sug-
est that more frequent and more aggressive treatment of
DL deficiency may be warranted in certain patients.
Consideration of lifestyle measures is always important.
n addition, niacin, fibrates, and statins can all raise
DL-C levels. The best choice of medication in low-
DL-C patients varies by individual circumstances.
Reverse cholesterol transport appears to play a large role
n the atheroprotective effect of HDL. However, other
roperties may also contribute to HDL-related cardiovas-
ular risk reduction and constitute potential targets for
uture drug therapy. In addition, HDL research will likely
ncrease our understanding of the link between atheroscle-
osis and metabolic disorders.
We expect that the coming decade will bring many new
lasses of therapies aimed at reducing cardiovascular risk.
he Working Group strongly advocates research into
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iencies. This could lead to the development of drugs that
re capable of enhancing HDL-related atheroprotec-
ion(41).
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